Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 16/20 | 1.00 |
| ▸ | CYP11B2 | P19099 | 14/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26669564 | 1.00 | CYP11B1 (1.00) | CYP11B1CYP11B2AKR1C3CES2CES1 | |
| SCHEMBL17723869 | 0.85 | CYP11B1 (1.00) | CYP11B1CYP11B2 | |
| SCHEMBL19212932 | 0.84 | CYP11B1 (1.00) | CYP11B1CYP11B2 | |
| SCHEMBL17714182 | 0.84 | CYP11B1 (1.00) | CYP11B1CYP11B2 | |
| SCHEMBL17714184 | 0.84 | CYP11B1 (1.00) | CYP11B1CYP11B2 | |
| SCHEMBL19212979 | 0.82 | CYP11B1 (1.00) | CYP11B1CYP11B2 | |
| SCHEMBL26813824 | 0.81 | CYP11B1 (0.73) | CYP11B1CYP11B2CES2CES1 | |
| SCHEMBL19212971 | 0.81 | CYP11B1 (0.68) | CYP11B1CYP11B2AKR1C3CES2CES1 | |
| SCHEMBL7802254 | 0.74 | AKR1C3 (0.62) | CYP11B1CYP11B2AKR1C3CES2CES1 | |
| SCHEMBL20508407 | 0.73 | CYP11B1 (0.60) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212636-B1 | NEW PYRIDINYLOXY- AND PHENYLOXY-PYRAZOLYL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2023-11-29 | — | — | EP | disclosed |
| US-9790217-B2 | Pyridinyloxy- and phenyloxy-pyrazolyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790217-B2 | Pyridinyloxy- and phenyloxy-pyrazolyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170226097-A1 | PYRIDINYLOXY- AND PHENYLOXY-PYRAZOLYL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170226097-A1 | PYRIDINYLOXY- AND PHENYLOXY-PYRAZOLYL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2017-08-10 | — | — | US | disclosed |
| WO-2016066664-A1 | NEW PYRIDINYLOXY- AND PHENYLOXY-PYRAZOLYL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226097-A1 | PYRIDINYLOXY- AND PHENYLOXY-PYRAZOLYL COMPOUNDS | PDXK, PNPO, PAH | CYP11B1 84/4885CYP11B2 32/4885AKR1C3 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.